Join Growin Stock Community!

Clearpoint neuro, inc.CLPT.US Overview

US StockHealthcare
(No presentation for CLPT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CLPT AI Insights

CLPT Overall Performance

CLPT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CLPT Recent Performance

-24.42%

Clearpoint neuro, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CLPT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CLPT Key Information

CLPT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CLPT Profile

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Price of CLPT

CLPT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CLPT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.78
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.89
PB Ratio
27.04
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
61.31%
Net Margin
-67.40%
Revenue Growth (YoY)
12.83%
Profit Growth (YoY)
14.57%
3-Year Revenue Growth
19.86%
3-Year Profit Growth
14.69%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.78
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.89
PB Ratio
27.04
Price-to-FCF
-
Gross Margin
61.31%
Net Margin
-67.40%
Revenue Growth (YoY)
12.83%
Profit Growth (YoY)
14.57%
3-Year Revenue Growth
19.86%
3-Year Profit Growth
14.69%
  • When is CLPT's latest earnings report released?

    The most recent financial report for Clearpoint neuro, inc. (CLPT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CLPT's short-term business performance and financial health. For the latest updates on CLPT's earnings releases, visit this page regularly.

  • What is the operating profit of CLPT?

    According to the latest financial report, Clearpoint neuro, inc. (CLPT) reported an Operating Profit of -5.28M with an Operating Margin of -59.54% this period, representing a decline of 2.01% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CLPT's revenue growth?

    In the latest financial report, Clearpoint neuro, inc. (CLPT) announced revenue of 8.86M, with a Year-Over-Year growth rate of 9.1%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CLPT have?

    As of the end of the reporting period, Clearpoint neuro, inc. (CLPT) had total debt of 35.75M, with a debt ratio of 0.59. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CLPT have?

    At the end of the period, Clearpoint neuro, inc. (CLPT) held Total Cash and Cash Equivalents of 38.22M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CLPT go with three margins increasing?

    In the latest report, Clearpoint neuro, inc. (CLPT) did not achieve the “three margins increasing” benchmark, with a gross margin of 63.2%%, operating margin of -59.54%%, and net margin of -66.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CLPT's profit trajectory and future growth potential.

  • Is CLPT's EPS continuing to grow?

    According to the past four quarterly reports, Clearpoint neuro, inc. (CLPT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CLPT?

    Clearpoint neuro, inc. (CLPT)'s Free Cash Flow (FCF) for the period is -3.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 174.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.